Nucleus RadioPharma is a new company built to ensure cancer patients can access potentially life-saving radiopharmaceuticals.
Nucleus RadioPharma has raised $50.0M in total funding. The most recent round was Private Equity. The last funding was announced in April 2026.
Nucleus RadioPharma's investors include Eclipse, AstraZeneca, OrbiMed, Mayo Clinic, GE Healthcare.
Nucleus RadioPharma is headquartered in Rochester, United States.
Nucleus RadioPharma is a new company built to ensure cancer patients can access potentially life-saving radiopharmaceuticals.
Nucleus RadioPharma is at the Private Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nucleus RadioPharma — Funding & Investors." VCBacked, April 20, 2026, https://www.vcbacked.co/company/nucleus-radiopharma. Accessed September 15, 2026.
VCBacked. (2026). Nucleus RadioPharma — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/nucleus-radiopharma
{{cite web |title=Nucleus RadioPharma — Funding & Investors |url=https://www.vcbacked.co/company/nucleus-radiopharma |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated